Meeting
2023 ASCO Annual Meeting
Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.
Authors
Kersti Oselin
North Estonia Medical Centre, Tallinn, Estonia
Kersti Oselin , Byoung Yong Shim , Morihito Okada , Maciej Bryl , Laura Bonanno , Guzin Demirag , Ida Colantonio , Martin Kimmich , Urska Janzic , Johan F. Vansteenkiste , Reyes Bernabe Caro , Amina Scherz , Alessandra Curioni-Fontecedro , Martin Früh , Mira Wollner , Jing Yang , Nazly Shariati , Sandrine Marreaud , Solange Peters , Mary ER O'Brien
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02504372
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8520)
DOI
10.1200/JCO.2023.41.16_suppl.8520
Abstract #
8520
Poster Bd #
147
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).
First Author: Mary E.R. O'Brien
Poster
2021 ASCO Annual Meeting
ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.
First Author: Toon Van Gorp
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.
First Author: Greg Andrew Durm
Poster
2018 ASCO Annual Meeting
Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.
First Author: Hiran C. Fernando